# BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

> **NCT02872259** · PHASE1,PHASE2 · COMPLETED · sponsor: **Haukeland University Hospital** · enrollment: 74 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** BGB324+pembrolizumab
- **DRUG:** BGB324+dabrafenib and trametinib
- **DRUG:** pembrolizumab
- **DRUG:** dabrafenib and trametinib

## Key facts

- **NCT ID:** NCT02872259
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-13
- **Primary completion:** 2024-05-23
- **Final completion:** 2024-05-23
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2025-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02872259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02872259, "BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02872259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*